579 related articles for article (PubMed ID: 26130168)
21. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
22. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
Lister-James J; Pontecorvo MJ; Clark C; Joshi AD; Mintun MA; Zhang W; Lim N; Zhuang Z; Golding G; Choi SR; Benedum TE; Kennedy P; Hefti F; Carpenter AP; Kung HF; Skovronsky DM
Semin Nucl Med; 2011 Jul; 41(4):300-4. PubMed ID: 21624563
[TBL] [Abstract][Full Text] [Related]
23. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
Camus V; Payoux P; Barré L; Desgranges B; Voisin T; Tauber C; La Joie R; Tafani M; Hommet C; Chételat G; Mondon K; de La Sayette V; Cottier JP; Beaufils E; Ribeiro MJ; Gissot V; Vierron E; Vercouillie J; Vellas B; Eustache F; Guilloteau D
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):621-31. PubMed ID: 22252372
[TBL] [Abstract][Full Text] [Related]
24. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
[TBL] [Abstract][Full Text] [Related]
26. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
Oh H; Madison C; Baker S; Rabinovici G; Jagust W
Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
[TBL] [Abstract][Full Text] [Related]
27. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.
Fleisher AS; Chen K; Liu X; Ayutyanont N; Roontiva A; Thiyyagura P; Protas H; Joshi AD; Sabbagh M; Sadowsky CH; Sperling RA; Clark CM; Mintun MA; Pontecorvo MJ; Coleman RE; Doraiswamy PM; Johnson KA; Carpenter AP; Skovronsky DM; Reiman EM
Neurobiol Aging; 2013 Jan; 34(1):1-12. PubMed ID: 22633529
[TBL] [Abstract][Full Text] [Related]
28. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.
Landau SM; Horng A; Fero A; Jagust WJ;
Neurology; 2016 Apr; 86(15):1377-1385. PubMed ID: 26968515
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations.
van Berckel BN; Ossenkoppele R; Tolboom N; Yaqub M; Foster-Dingley JC; Windhorst AD; Scheltens P; Lammertsma AA; Boellaard R
J Nucl Med; 2013 Sep; 54(9):1570-6. PubMed ID: 23940304
[TBL] [Abstract][Full Text] [Related]
30. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.
Verhoeff NP; Wilson AA; Takeshita S; Trop L; Hussey D; Singh K; Kung HF; Kung MP; Houle S
Am J Geriatr Psychiatry; 2004; 12(6):584-95. PubMed ID: 15545326
[TBL] [Abstract][Full Text] [Related]
31. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
Okamura N; Yanai K
IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
[TBL] [Abstract][Full Text] [Related]
32. Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages.
Pereira JB; Strandberg TO; Palmqvist S; Volpe G; van Westen D; Westman E; Hansson O;
Cereb Cortex; 2018 Jan; 28(1):340-349. PubMed ID: 29136123
[TBL] [Abstract][Full Text] [Related]
33. The evaluation of brain perfusion SPECT using an easy Z-score imaging system in the mild cognitive impairment subjects with brain amyloid-β deposition.
Takemaru M; Kimura N; Abe Y; Goto M; Matsubara E
Clin Neurol Neurosurg; 2017 Sep; 160():111-115. PubMed ID: 28715708
[TBL] [Abstract][Full Text] [Related]
34. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.
Nordberg A; Carter SF; Rinne J; Drzezga A; Brooks DJ; Vandenberghe R; Perani D; Forsberg A; Långström B; Scheinin N; Karrasch M; Någren K; Grimmer T; Miederer I; Edison P; Okello A; Van Laere K; Nelissen N; Vandenbulcke M; Garibotto V; Almkvist O; Kalbe E; Hinz R; Herholz K
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):104-14. PubMed ID: 22961445
[TBL] [Abstract][Full Text] [Related]
35. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study.
Boccardi M; Altomare D; Ferrari C; Festari C; Guerra UP; Paghera B; Pizzocaro C; Lussignoli G; Geroldi C; Zanetti O; Cotelli MS; Turla M; Borroni B; Rozzini L; Mirabile D; Defanti C; Gennuso M; Prelle A; Gentile S; Morandi A; Vollaro S; Volta GD; Bianchetti A; Conti MZ; Cappuccio M; Carbone P; Bellandi D; Abruzzi L; Bettoni L; Villani D; Raimondi MC; Lanari A; Ciccone A; Facchi E; Di Fazio I; Rozzini R; Boffelli S; Manzoni L; Salvi GP; Cavaliere S; Belotti G; Avanzi S; Pasqualetti P; Muscio C; Padovani A; Frisoni GB;
JAMA Neurol; 2016 Dec; 73(12):1417-1424. PubMed ID: 27802513
[TBL] [Abstract][Full Text] [Related]
37. Predicting cognitive decline with deep learning of brain metabolism and amyloid imaging.
Choi H; Jin KH;
Behav Brain Res; 2018 May; 344():103-109. PubMed ID: 29454006
[TBL] [Abstract][Full Text] [Related]
38. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
39. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
Hatashita S; Wakebe D
J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
[TBL] [Abstract][Full Text] [Related]
40. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
